ScripNovartis has posted a healthy set of financials for the second quarter with strong growth for its new cancer therapies and Entresto, and is raising its earnings guidance for 2025 despite imminent gene
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
Generics BulletinMSN Laboratories’ proposed generic version of Novartis’ Entresto (sacubitril/valsartan) has been paused temporarily by the US Court of Appeals for the Federal Circuit, after the Indian firm inched clo